Safety and tolerability endpoints of AEs; EEG; ECGs; neurological assessments; vital signs and clinical laboratory values.Part A PK parameters of Cmax,AUC,t1/2,Tmax,Ae(0-t).Part B PK parameters of Cmax,Tmax,t1/2,AUC and accumulation ratio.
Pharmacodynamic effects on Bond-Lader,Body Sway and EEG and the relationship of plasma levels of GSK729327 with pharmacodynamic parameters.Part B will also look atcognitive function,Polysomnography and LSEQ.
18 Years to 55 Years (Adult)
March 19, 2007
October 15, 2010
GSK Investigational Site Berlin, Germany
GSK Investigational Site London, United Kingdom
† Study has passed its completion date and status has not been verified in more than two years.